The use of postmenopausal hormone treatment has decreased over time in the United States, which scientists suggest may play a key role in the declining rate of atypical ductal hyperplasia, a known risk factor for breast cancer. "Postmenopausal hormone therapy is linked to increased rates of non-malignant breast biopsies, and early and late stages of cancer. Atypical ductal hyperplasia is linked to the use of postmenopausal hormone therapy and its rates have decreased with the decline in use of this therapy," said researcher Tehillah Menes, M.D., who was the chief of breast service in the Department of Surgery at Elmhurst Hospital Center, New York, when this study was conducted........